Crispr Therapeutics AG (CRSP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on the stock and has a $97.00 price target.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG’s promising growth prospects. The company is experiencing a strong launch of Casgevy, with robust payer coverage and strategic positioning in key markets such as the US, Middle East, and EU. This launch is expected to drive significant revenue, positioning Casgevy as a potential multi-billion dollar drug.
Additionally, Crispr Therapeutics AG’s pipeline includes CTX112, which shows potential to outperform existing autologous CARTs in autoimmune diseases due to its favorable safety profile and pricing advantages. The company’s in vivo cardiovascular programs, such as CTX310 and CTX320, offer promising opportunities for diversification and improved clinical outcomes. These factors, combined with the company’s substantial cash reserves and upcoming clinical readouts, suggest that Crispr Therapeutics AG is undervalued and well-positioned for future profitability.
In another report released on April 17, Bank of America Securities also maintained a Buy rating on the stock with a $80.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year.